Ethosuximide should not be used for routine management of irritable bowel syndrome–related abdominal pain given the lack of demonstrated benefit and reduced tolerability in this trial. Physicians should continue to follow established guideline-recommended therapies. Further research into more selective T-type calcium channel modulators may clarify whether this mechanism has future therapeutic potential.

Source: JAMA Network Open